Quest Diagnostics (DGX), on Monday, said it has decided to introduce clinical laboratory testing using Ki-67 IHC MIB-1 pharmDx (Dako Omnis) immunohistochemistry companion diagnostic.
The Ki-67 IHC MIB-1 pharmDx (Dako Omnis), from Agilent Technologies Inc, was approved by the FDA as an aid in identifying patients with early breast cancer at high risk of disease recurrence, for whom adjuvant treatment with Eli Lilly and Co.'S (LLY) Verzenio in combination with endocrine therapy is being considered.
Quest Diagnostics, which is the first laboratory to validate Ki-67 IHC MIB-1 pharmDx (Dako Omnis), plans to make testing available nationally by the end of October.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.